121 related articles for article (PubMed ID: 37054556)
1. Gemcitabine plus platinum-based chemotherapy in combination with bevacizumab for kidney metastatic collecting duct and medullary carcinomas: Results of a prospective phase II trial (BEVABEL-GETUG/AFU24).
Thibault C; Fléchon A; Albiges L; Joly C; Barthelemy P; Gross-Goupil M; Chevreau C; Coquan E; Rolland F; Laguerre B; Gravis G; Pécuchet N; Elaidi RT; Timsit MO; Brihoum M; Auclin E; de Reyniès A; Allory Y; Oudard S
Eur J Cancer; 2023 Jun; 186():83-90. PubMed ID: 37054556
[TBL] [Abstract][Full Text] [Related]
2. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
[TBL] [Abstract][Full Text] [Related]
6. An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Patil PD; Shapiro M; Hashemi Sadraei N; Pennell NA
Oncologist; 2019 Apr; 24(4):457-e126. PubMed ID: 30602615
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma.
Wilson NR; Wiele AJ; Surasi DS; Rao P; Sircar K; Tamboli P; Shah AY; Genovese G; Karam JA; Wood CG; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Dec; 19(6):e401-e408. PubMed ID: 34625389
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Dudek AZ; Kumar P; H Thaw SS; Cao Q; Pawloski P; Larson T
Am J Clin Oncol; 2014 Apr; 37(2):140-3. PubMed ID: 23111363
[TBL] [Abstract][Full Text] [Related]
10. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
[TBL] [Abstract][Full Text] [Related]
11. Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Nasu H; Nishio S; Park J; Yoshimitsu T; Matsukuma K; Tasaki K; Katsuda T; Terada A; Tsuda N; Ushijima K
Int J Clin Oncol; 2022 Apr; 27(4):790-801. PubMed ID: 34985551
[TBL] [Abstract][Full Text] [Related]
12. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
13. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
14. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.
Rini BI; Halabi S; Rosenberg JE; Stadler WM; Vaena DA; Archer L; Atkins JN; Picus J; Czaykowski P; Dutcher J; Small EJ
J Clin Oncol; 2010 May; 28(13):2137-43. PubMed ID: 20368558
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Hensley ML; Miller A; O'Malley DM; Mannel RS; Behbakht K; Bakkum-Gamez JN; Michael H
J Clin Oncol; 2015 Apr; 33(10):1180-5. PubMed ID: 25713428
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
19. Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.
Guillaume Z; Colomba E; Thouvenin J; Saldana C; Campedel L; Dumont C; Laguerre B; Maillet D; Vicier C; Rolland F; Borchiellini D; Barthelemy P; Albiges L; Auclin E; Roulleaux Dugage M; Oudard S; Thibault C
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406448
[TBL] [Abstract][Full Text] [Related]
20. Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.
Motzer RJ; Powles T; Atkins MB; Escudier B; McDermott DF; Alekseev BY; Lee JL; Suarez C; Stroyakovskiy D; De Giorgi U; Donskov F; Mellado B; Banchereau R; Hamidi H; Khan O; Craine V; Huseni M; Flinn N; Dubey S; Rini BI
JAMA Oncol; 2022 Feb; 8(2):275-280. PubMed ID: 34940781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
